Skip to main content

Advertisement

SpringerLink
Log in

F508del-CFTR is not corrected by thymosin α1

  • Correspondence
  • Published:

From Nature Medicine

View current issue Submit your manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Effects of Tα1 on CFTR function in bronchial epithelial cells homozygous for the p.Phe508del mutation.

References

  1. Riordan, J. R. et al. Science 245, 1066–1073 (1989).

    Article  PubMed  CAS  Google Scholar 

  2. Romani, L. et al. Nat. Med. 23, 590–600 (2017).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  3. Goldstein, A. L. & Badamchian, M. Expert Opin. Biol. Ther. 4, 559–573 (2004).

    Article  PubMed  CAS  Google Scholar 

  4. Cantin, A. M. & Hanrahan, J. W. Nat. Med. 23, 536–538 (2017).

    Article  PubMed  CAS  Google Scholar 

  5. Fulcher, M. L., Gabriel, S., Burns, K. A., Yankaskas, J. R. & Randell, S. H. in Human Cell Culture Protocols vol. 107 (ed. Picot, J.) 183–206 (Humana Press, New York, 2005).

  6. Robert, R. et al. Mol. Pharmacol. 73, 478–489 (2008).

    Article  PubMed  CAS  Google Scholar 

  7. Van Goor, F. et al. Proc. Natl. Acad. Sci. USA 108, 18843–18848 (2011).

    Article  PubMed  CAS  Google Scholar 

  8. Robert, R. et al. Mol. Pharmacol. 77, 922–930 (2010).

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

We thank J. Goepp and the Primary Airway Cell Biobank (McGill University) for providing HBE cells, and we thank J. Hong and E. Sorscher (Emory University) for the CFBE41o- cell lines expressing p.Phe508del-CFTR. This work was supported by grants from CF Canada (2997) and the Canadian Institutes of Health Research (287879).

Author information

Authors and Affiliations

  1. Department of Physiology, McGill University, Montréal, Québec, Canada

    Elizabeth Matthes & John W. Hanrahan

  2. Cystic Fibrosis Translational Research Centre, McGill University, Montréal, Québec, Canada

    Elizabeth Matthes, John W. Hanrahan & André M. Cantin

  3. Research Institute of McGill University Hospital Centre, Montréal, Québec, Canada

    John W. Hanrahan

  4. Service de Pneumologie, Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Sherbrooke, Québec, Canada

    André M. Cantin

Authors
  1. Elizabeth Matthes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John W. Hanrahan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. André M. Cantin
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

E.M. contributed to the design of the study, conducted the experiments and prepared the figure and figure legend. J.W.H. conceived and planned the experiments, analyzed the data and helped write the manuscript. A.M.C. helped write the manuscript with input from the other authors and supervised the project.

Corresponding author

Correspondence to André M. Cantin.

Ethics declarations

Competing interests

A.M.C. has received honoraria as a speaker and consultant from Vertex Pharmaceuticals in 2016–2018. J.W.H. is cofounder and shareholder of Traffick Therapeutics, Inc. He consults for Engelhard Arzneimittel GmbH & Co., ERAD Therapeutics and Vertex Pharmaceuticals. Research funding is provided to his laboratory by Verona Pharma plc, Engelhard Arzneimittel GmbH & Co., and ERAD Therapeutics. J.W.H. has patent applications (awarded or pending) as co-inventor with Traffick Therapeutics (USPTO 62/306,287, Montreal, Canada), Verona Pharma (WO2015173551A1, Cardiff, UK) and Laurent Pharmaceuticals (USPTO 62/658,001, Montreal, Canada). J.W.H. is director of the CFTRc, which has a seminar series supported by Vertex. None of the investments, consulting activities or patents are related to Tα1.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Matthes, E., Hanrahan, J.W. & Cantin, A.M. F508del-CFTR is not corrected by thymosin α1. Nat Med 24, 890–891 (2018). https://doi.org/10.1038/s41591-018-0079-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-018-0079-6

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation